EGFR and non-small cell lung carcinoma: The BR2-2xPPD peptide treatment of NSCLC with wild-type EGFR effectively induced cell cycle arrest and decreased numbers of proliferative cells, while EGFR-TKIs, including Gefitinib and Erlotinib, failed to inhibit cell proliferation of NSCLC with wild-type EGFR (Fig 3).